In 2018, Sun et al. revealed that CD36 could negatively regulate insulin activation; CD36 interacts with IRS-1 and, thus, abrogates the binding between IRS-1 and Cul7, which further increases IRS-1 stability, thereby affecting insulin signaling and ultimately resulting in tumor suppression [32]. The gene discussed is CD36; the disease is neoplasm.